Current stock page

Stock Analysis

Haemonetics Corporation (HAE) Stock Analysis

Haemonetics Corporation (HAE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

HAE Stock Analysis Summary

Haemonetics Corporation (HAE) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 60/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data

HAE at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$122.86
AIQ Score77/100
Overall ViewBullish
Technical Analysis ConsensusStrong Buy
Market Cap$5.59B
P/E Ratio (TTM)53.27
Forward P/E—
EPS (Q2 FY2027)$1.02
Revenue (Q2 FY2027)$357.76M
Dividend Yield (TTM)0.00%
Beta0.24
Volume486.37K
52-week range$51.00-$132.00
RSI 1458.75
50-Day SMA$113.31
200-Day SMA$81.26
Analyst Price Target$140.17
Next EarningsFeb 4, 2027
As of Nov 18, 2026 · Market close

HAEHaemonetics Corporation

Healthcare / Medical - Devices

Leader

Sector Leader

BullishEdge 10/10
$122.86+$1.94 (+1.60%)

Latest quote

  • Momentum
    91
  • Value
    60
  • Quality
    77
  • Risk resilience
    67
  • Sentiment
    —
algovestiq.comScore data as of Nov 18, 2026

HAE Stock Analysis Summary

Haemonetics Corporation (HAE) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 91/100. Value is the weakest current factor at 60/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 18, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, HAE has AIQ Score of 77/100 with Momentum base of 91/100 and fading Value at 60/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (91/100) leads while Value (60/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · 1.60% stock move · HAE classified in Medical - Devices.

Current Evidence

BullishHAE is in a bullish AIQ regime; Momentum is the strongest visible factor at 91/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is HAE Bullish or Bearish Right Now?

HAE currently has a bullish overall setup. Momentum is the strongest factor at 91/100, while Value is weakest at 60/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 77/100.
  • - Momentum is constructive at 91/100.
  • - Risk Resilience is supportive at 67/100.
  • - Price is +8.50% above its 50-day SMA.
  • - Analyst target implies +14.09% upside from the latest quote.
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

HAE's Technical Analysis Consensus is currently Strong Buy, with 33 buy, 7 neutral, and 6 sell votes. HAE's 14-day RSI is 58.75, which places the stock in a constructive momentum range. HAE's beta is 0.24, indicating lower market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in HAE?

The largest recent change in HAE is Momentum moving down by 2.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+0.0
Momentum
-2.0
Quality
+0.0
Risk
+0.0

What Would Change the HAE Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

HAE Decision Framework

Public evidence layers, setup checks, and risk context for Haemonetics Corporation.

Haemonetics Corporation (HAE) Stock Analysis

Haemonetics Corporation has an AIQ Score of 77/100 in a Bullish regime. Momentum is strongest at 91/100. Beta is 0.24, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextHAE is in a Bullish AIQ regime with score 77/100.
Signal ConflictThe primary conflict is that momentum leads at 91/100 while value lags at 60/100.
Factor EvidenceMomentum 91/100 · Value 60/100 · Quality 77/100 · Risk 67/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 91/100.

TimingPass

Momentum is 91/100 and RSI (14) is 58.7.

Regime fitPass

HAE is in a Bullish regime at 77/100.

Risk controlPass

Risk factor is 67/100 with beta 0.24 and annual volatility 41.04%.

ConflictWait

Current conflict: momentum leads at 91/100 while value lags at 60/100.

AIQ Score
77/100
Price
$122.86
Beta
0.24
RSI (14)
58.7

HAE Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

HAE Fundamentals

HAE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$357.76M
Net income
$46.31M
Free cash flow
$118.89M
View full HAE fundamental analysis

HAE Technical Analysis

HAE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
58.75
Price vs SMA-50
+8.50%
View full HAE technical analysis

HAE Stock Catalysts

Track HAE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 4, 2027
Analyst target
$140.17
News items
4
View HAE earnings and stock catalysts

HAE Dividend Analysis

HAE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View HAE dividend history and analysis

HAE Financial Data

HAE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$357.76M
EPS
$1.02
Periods
8
View HAE financials

HAE Risk Analysis

HAE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.24
Risk score
67/100
1Y volatility
41.04%
View HAE risk analysis

HAE Stock News

HAE stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 18, 2026
Sentiment
—
Read HAE stock news

HAE vs Medical - Devices Peers

Current peer cohort: HAE · IRTC · ITGR · LIVN · NEOG. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
HAE
Current stock
77/10060/10091/10067/1001.3541.04%Current
IRTC
iRhythm Technologies, Inc.
44/10043/10034/10044/100-0.9154.02%HAE vs IRTC
ITGR
Integer Holdings Corporation
——85/10080/1002.0231.24%HAE vs ITGR
LIVN
LivaNova PLC
71/10060/10083/10071/1001.3839.16%HAE vs LIVN
NEOG
Neogen Corporation
63/10049/10074/10057/1001.1957.93%HAE vs NEOG
Pairwise Compare links: IRTC · ITGR · LIVN · NEOGHAE vs IRTCHAE vs ITGRHAE vs LIVNHAE vs NEOGCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 18, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 18, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a HAE stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for HAE: historical return with reinvested dividends, dollar-cost averaging (DCA) backtest and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 19, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
53.27
As of Nov 18, 2026
Revenue growth
9.30%
Gross margin
58.83%
Current debt / equity
1.25
Latest quarterly evidence

Latest period Sep 26, 2026.

Review fundamentals
Quarter revenue
$357.76M
Quarter net income
$46.31M
Quarter free cash flow
$118.89M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
58.75
MACD
2.53

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
67/100
Beta
0.24
Annual volatility
41.04%
Max drawdown
-40.06%

HAE Stock FAQ

What is HAE stock price today?

Haemonetics Corporation's current stock price is $122.86. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is HAE bullish or bearish right now?

HAE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is HAE's market cap?

HAE's market cap is $5.59B based on the latest completed market-close snapshot from Nov 18, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is HAE's current P/E ratio?

HAE's current P/E ratio is 53.27 based on the latest completed market-close snapshot from Nov 18, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is HAE's RSI?

HAE's 14-day RSI is 58.75 based on the latest completed market-close snapshot from Nov 18, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is HAE above its 50-day and 200-day moving averages?

HAE is 8.50% from its 50-day SMA and 51.29% from its 200-day SMA based on the latest completed market-close snapshot from Nov 18, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is HAE's next earnings date?

HAE's next earnings date is currently listed as Feb 4, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does HAE pay a dividend?

HAE's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 18, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.